Activity Overview
Biomarker-driven advancements, including immune checkpoint inhibitors and antibody-drug conjugates targeting HER2 and TROP2, have provided critical options for patients with endometrial cancer. However, disparities in access have meant these advancements do not reach all patients who might benefit from them.
In this spotlight symposium, presented at the 17th Annual International Symposium on Gynecologic Malignancies, case-based discussions explore epidemiology, inequalities, and current and emerging immunotherapy options for patients with endometrial cancer. Expert faculty provide invaluable clinical pearls and practical strategies to help learners apply trial data to the clinical setting.
This educational activity is an archive
of the live virtual symposium held on May 9, 2026.
Target Audience
This educational activity is directed toward oncologists,
gynecologists, nurses, nurse practitioners, physician assistants, and other health
care professionals involved in the diagnosis and treatment of endometrial
cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe the evidence for contemporary and emerging biomarker testing strategies in individualizing therapy for patients with endometrial cancer
- Evaluate recent clinical trial data for the use of biomarker-driven therapies in advanced and recurrent endometrial cancer
- Apply shared decision-making strategies to develop personalized treatment plans that reflect molecular findings, patient goals, and access considerations
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
